NCT01902862 2014-04-01
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
Janssen-Cilag G.m.b.H
Phase 2 Terminated
Clinical Trials
5 trialsNCT00715208 2013-04-29
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00850499 2012-12-12
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00636792 2012-01-13
VERTICAL
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00085696 2008-02-11
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed